SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Dicerna Pharmaceuticals Q1 EPS $(0.310) May Not Compare To $0.270 Estimate, Sales $34.028M May Not Compare To $59.830M Estimate

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.310) per share which missed the analyst consensus estimate of $0.270 by 214.81 percent. This is a 18.42 percent increase over losses of $(0.380) per

Benzinga · 05/07/2020 20:53

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.310) per share which missed the analyst consensus estimate of $0.270 by 214.81 percent. This is a 18.42 percent increase over losses of $(0.380) per share from the same period last year. The company reported quarterly sales of $34.028 million which missed the analyst consensus estimate of $59.830 million by 43.13 percent. This is a 995.20 percent increase over sales of $3.107 million the same period last year.